The estimated Net Worth of Andrew D Sklawer is at least $293 mil dollars as of 17 May 2021. Mr. Sklawer owns over 15,375 units of Brickell Biotech Inc stock worth over $292,869 and over the last 5 years he sold BBI stock worth over $0. In addition, he makes $0 as Co-Founder, Chief Operating Officer y Secretary at Brickell Biotech Inc.
Sign up
Mr. Sklawer BBI stock SEC Form 4 insiders trading
Andrew has made over 3 trades of the Brickell Biotech Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 15,375 units of BBI stock worth $12,300 on 17 May 2021.
The largest trade he's ever made was exercising 20,000 units of Brickell Biotech Inc stock on 16 March 2021 worth over $47,000. On average, Andrew trades about 6,917 units every 47 days since 2020. As of 17 May 2021 he still owns at least 124,625 units of Brickell Biotech Inc stock.
You can see the complete history of Mr. Sklawer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Andrew Sklawer biography
Andrew D. Sklawer is Co-Founder, Chief Operating Officer, Secretary of the Company. Mr. Sklawer has served as Brickell’s Chief Operating Officer and Secretary since its inception in 2009 and is one of its founders. Prior to co-founding Brickell, Mr. Sklawer served as the Head of Operations at Concordia Pharmaceuticals, Inc., an oncology drug development company that was acquired by Kadmon Corporation in 2011. Prior to joining Concordia, Mr. Sklawer held various positions at Verid, Inc., a developer of security technology prior to its acquisition by EMC Corporation. Mr. Sklawer holds a B.A. in marketing from the University of Florida and earned his M.B.A. from the University of Miami. Mr. Sklawer currently serves as a board member for StartUp FIU, a Florida International University platform that supports researchers, inventors, innovators, and entrepreneurs to conceive, launch, and scale solutions, is a member of the Advisory Committee of Advancing Innovation in Dermatology Accelerator Fund and is a board member of the Colorado BioScience Association.
How old is Andrew Sklawer?
Andrew Sklawer is 36, he's been the Co-Founder, Chief Operating Officer y Secretary of Brickell Biotech Inc since 2019. There are 15 older and 2 younger executives at Brickell Biotech Inc. The oldest executive at Brickell Biotech Inc is Albert Nicholas Marchio II, 69, who is the Chief Financial Officer.
What's Andrew Sklawer's mailing address?
Andrew's mailing address filed with the SEC is C/O BRICKELL BIOTECH, INC., 5777 CENTRAL AVENUE, SUITE 102, BOULDER, CO, 80301.
Insiders trading at Brickell Biotech Inc
Over the last 5 years, insiders at Brickell Biotech Inc have traded over $0 worth of Brickell Biotech Inc stock and bought 584,350 units worth $353,337 . The most active insiders traders include Vijay B Samant, Monica E. Luchi y Gary A Lyons. On average, Brickell Biotech Inc executives and independent directors trade stock every 16 days with the average trade being worth of $51,782. The most recent stock trade was executed by Reginald L Hardy on 23 July 2021, trading 200,000 units of BBI stock currently worth $134,000.
What does Brickell Biotech Inc do?
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell's executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell's strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs.
What does Brickell Biotech Inc's logo look like?
Complete history of Mr. Sklawer stock trades at Brickell Biotech Inc
Brickell Biotech Inc executives and stock owners
Brickell Biotech Inc executives and other stock owners filed with the SEC include:
-
Vijay Samant,
Director -
Attorney Robert Busard Brown,
CEO & Director -
Deepak Chadha,
Chief R&D Officer -
Reginald L. Hardy M.B.A., R.Ph.,
Co-Founder & Chairman -
Dennison Veru,
Director -
Gary Lyons,
Director -
Adam Levy,
Chief Business Officer -
Deepak Chadha,
Chief Research and Development Officer -
David McAvoy,
Chief Compliance Officer, General Counsel, Assistant Secretary -
Jose Breton,
Chief Accounting Officer, Controller -
R. Carruthers,
Chief Financial Officer -
Andrew Sklawer,
Co-Founder, Chief Operating Officer, Secretary -
Robert Brown,
Chief Executive Officer, Director -
Reginald Hardy,
Chairman of the Board, Co-Founder -
Sue Fattor,
Head of Human Resource -
Aron Aizenstat M.B.A., P.M.P.,
VP of Corp. Devel. & Operations -
Gary S. Walker,
Chief Marketing Officer -
David R. Mcavoy J.D.,
Gen. Counsel & Chief Compliance Officer -
Jose Breton,
Controller & Chief Accounting Officer -
Albert Nicholas Marchio II,
Chief Financial Officer -
Sanjeev Ahuja,
Chief Medical Officer -
George B Abercrombie,
CHIEF EXECUTIVE OFFICER -
Monica E. Luchi,
Chief Medical Officer -
Albert N Ii Marchio,
Chief Financial Officer